Reduced cellular accumulation of topotecan: A novel mechanism of resistance in a human ovarian cancer cell line

British Journal of Cancer

Volumn 77, Issue 10, 1998, Pages 1645-1652

  Ma, J ^a   Maliepaard, M ^b   Nooter, K ^a   Loos, W J ^a   Kolker, H J ^a   Verweij, J ^a   Stoter, G ^a   Schellens, J H M ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Accumulation; Camptothecin; Cell line; Irinotecan; Resistance; Topoisomerase I; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; TOPOTECAN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG RESISTANCE; DRUG TRANSPORT; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031961234     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.270     Document Type: Article

References (42)

1. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y and Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569
2. Beijnen JH, Smith BR, Keijer WJ, Van Gijn R, Ten Bokkel-Huinink WW, Vlasveld LT, Rodenhuis S and Underberg WJM (1990) High-performance liquid chromatographic analysis of the new antitumour drug SF&F 1104864-A (NSC 609699) in plasma. J Pharmaceut Biomed Anal 8: 789-794
3. Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72: 248-254
4. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou T-C, Sun M, Pulliam S and Gonzalez C (1996) Irinotecan is an active agent in untreated patients with metastatic colectoral cancer. J Clin Oncol 14: 709-715
5. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP and Johnson RK (1990) Development of a stable camptothecin-resislant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38: 471-480
6. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ and Zaman GJR (1994) Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 54: 4557-4563
7. Fujimori A, Harker WG, Kohlhagen G, Hoki Y and Pommier Y (1995) Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 55: 1339-1346
8. Gallo RC, Whang Peng J and Adamson RH (1971) Studies of the antitumour activity, mechanism of action and the cell cycle effects of camptothecin. J Natl Cancer Inst 46: 789-795
9. Garg LCS, Diangelo S and Jacob ST (1987) Role of DNA topoisomerase I in the transcription of supercoiled rRNA gene. Proc Natl Acad Sci USA 84: 3185-3188
10. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048
11. Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T and Salmon S (1990) Optimization of immunocytochemical P-glycoprotein assessment in muultidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 63: 815-824
12. Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SP and Kuwano M (1995) Expression of multidrug resistance-associated protein (MRP). MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71: 907-913
13. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278
14. Hsiang Y-H, Hertzberg R, Hecht S and Liu LF (1985) Camptothecin induces protein-lined DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878
15. Hsiang Y.-H, Lihou MG and Liu LF (1989) Arrest of replication forks by drugstabilized topoisomerase 1-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082
16. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF and Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5919-5924
17. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 58: 351-375
18. Liu LF and Miller KG (1981) Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78: 3487-3491
19. Loos WJ, Stoter G, Verweij J and Schellens JHM (1996) Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. J Chromatogr B-Bio Med Appl 678: 309-315
20. Madelaine I, Prost S, Naudin A, Riou G, Lavelle F and Riou J.-F (1993) Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol 45: 339-348
21. Maliepaard M, Nooter K, Ma J, Loos WJ, Kolker HJ, Verweij J, Stoter G and Schellens JHM (1996) Relationship between P-glycoprotein, multidrug resistance-associated protein, and cellular accumulation of topoisomerase I inhibitors (abstract) Proc Am Assoc Cancer Res 37: 313
22. Mattern MR, Hofmann GA, Polsky RM and Johnson RK (1993) Cross resistance of MDR. P-glycoprotein overexpressing CHO cells to camptothecin analogues (abstract). Proc Am Assoc Cancer Res 34: 424
23. Nooter K, Westerman AM, Flens MJ, Zaman GJR, Scheper RJ, Van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, Gratama JW, Kok T, Eggermont AMM, Bosman FT and Stoter G (1995) Expression of the multidrug resistance associated protein (MRP) gene in human cancers. Clin Cancer Res 1: 1301-1310
24. Pantazis P, Mendoza J, Dejesus A, Early J, Shaw M and Giovanella BC (1994) Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs. Anti Cancer Drugs 5: 473-479
25. Potmesil M (1994) Camptothecins: from bench research to hospital wards. Cancer Res 54: 1431-1439
26. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS,. Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH and Donehower RC (1992) Phase I and pharmacologic study of topotecan: a novel topoisomerse I inhibitor. J Clin Oncol 10: 647-656
27. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng Y, Grochow LB and Kaufmann SH (1994) Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12: 2193-2203
28. Sinha BK (1995) Topoisomerase inhibitors. A review of their therapeutic potential in cancer Drugs 49: 11-19
29. Sirotnak FM, Yang CH, Mines LS, Oribe E and Biedler JL (1986) Markedly altered membrane transport and intracellular binding of vincristine in multidrug-resistant Chinese hamster cells selected for resistance to vinca alkaloids. J Cell Physiol 126: 266-274
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
31. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH (1993) The current status of camptothecin analogues as antitumour agents. J Natl Cancer Inst 85: 271-291
32. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Löwenberg B and Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255-259
33. Sorensen M, Sehested M and Jensen PB (1995) Characterisation of human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 72: 399-404
34. Sugimoto Y, Tsukahara S, Oh-Hara T, Isoe T and Tsuruo T (1990) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-6930
35. Tanizawa A, Fujimori A, Fujimori Y and Pommier Y (1994) Comparison of topoisomerase I inhibition. DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842
36. Van Der Zee AGJ, Hollema H, De Jong S, Boonstra H, Gouw A, Willemse PHB, Zijlstra JG and De Vries EGE (1991) P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumours of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915-5920
37. Versantvoort CHM, Broxterman HJ, Pinedo HM, De Vries EGE, Feller N, Kuiper CM and Lankelma J (1992) Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines wilhout P-glycoprotein expression. Cancer Res 52: 17-23
38. Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ and Twentyman PR (1995) Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72: 82-89
39. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665-697
40. Yang C.-H, llonon JK, Cowan KH and Schneider E (1995) Cross-resistance to camptothecin analogues in a mitoxanthrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I. Cancer Res 55: 4004-4009
41. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, De Haas M, Smith AJ, Broxterman HJ, Mulder NH, De Vries EGE, Baas F and Borst P (1993) Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747-1750
42. Zaman GJR, Lankelma J, Van Tellingen O, Beijnen J, Dekker H, Paulusma C, Onde Elferink RPJ, Baas F and Borst P (1995) Role of glutathione in the export of compounds from cells by the multidrug-resistance-assocated protein. Proc Natl Acad Sci USA 92: 7690-7694